How much funding has XELTIS raised?

XELTIS has raised $159.0M in total funding, most recently a Series D round.

Where is XELTIS headquartered?

XELTIS is headquartered in Eindhoven, Netherlands.

What industry is XELTIS in?

XELTIS operates in Biotech, Healthcare.

XELTIS

Q: Who are XELTIS's investors?

XELTIS's investors include European Innovation Council Fund, European Investment Bank, DaVita Venture Group, Ysios Capital, EQT AB.

Eindhoven, Netherlands · Founded 2006 · $159.0M raised

Biotech

Healthcare

Headquarters: Eindhoven
Employees: 51–200
Founded: 2006
Business Model: B2B

Website: xeltis.com
Total Funding: $159.0M
Last Round: $48.0M Series DFeb 2023
Rounds: 5

About

Xeltis is a medtech company developing transformative vascular implants that leverage its proprietary endogenous tissue restoration (ETR) platform to enable the natural creation of living, long-lasting tissue. Founded in 2006 as a University of Zurich spin-off and headquartered in the Netherlands, Xeltis uses Restorex®, a Nobel Award-winning supramolecular polymer manufactured via electrospinning, to create restorative grafts and valves that gradually integrate with patients' own tissue — targeting hemodialysis vascular access and cardiovascular replacement markets.

Summary

XELTIS is a Biotech company based in Eindhoven, Netherlands, founded in 2006. It has raised $159.0M in total across 5 rounds, most recently a $48.0M Series D round in Feb 2023. Investors include European Innovation Council Fund, European Investment Bank and DaVita Venture Group.